Price T Rowe Associates Inc Taysha Gene Therapies, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,099,329 shares of TSHA stock, worth $3.77 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,099,329
Previous 1,227,333
10.43%
Holding current value
$3.77 Million
Previous $2.17 Million
45.24%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
111Shares Held
109MCall Options Held
108KPut Options Held
158K-
Avoro Capital Advisors LLC New York, NY18.7MShares$64 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$63.8 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$30.9 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$20.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.17MShares$17.7 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $166M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...